X

Trial Profile

Phase 1/2A dose range finding study of IRL201805 in patients with active rheumatoid arthritis who had failed one or more standard therapies

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 21 May 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IRL 201805 (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Immune Regulation; Revolo Biotherapeutics

Most Recent Events

16 May 2022 According to a Revolo Biotherapeutics media release, this trial will be reviewed at the at two upcoming medical meetings: the American Thoracic Society (ATS) International Conference and the Treg Summit.
09 Sep 2020 New trial record
08 Sep 2020 Results published in the Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com